Movement Disorders

The professor of neurology provided insight into the field of deep brain stimulation and how Abbott's recent FDA approval is a solid step forward.

Abbott’s Infinity Deep Brain Stimulator now allows for performance of MRI on patients with Parkinson or essential tremor with the system implanted.

A small but noteworthy study examined whether DBS could improve motor symptoms in early PD.

Psychosis symptoms in patients with Parkinson disease can turn a difficult situation into an untenable one: they are the leading reason that patients leave their homes for continued care in a skilled nursing facility.

The FDA had accepted a new drug application for APL-130277, a sublingual film version of apomorphine, as a treatment for OFF episodes in patients with Parkinson disease.

Across 3 cohorts, the therapy showed improvements in on-time without troublesome dyskinesia, ranging from 2.1 hours to 3.5 hours.

An update on the prevalence and features of demoralization in patients with PD.

New research highlights prevention, diagnostic, and treatment advances for Alzheimer, autism, atherosclerosis, and more.

Levels of calcium inside nerve cells seem to decrease early in PD, and then increase later on-a finding that stresses the importance of treatment throughout the entire course of the illness.

New technology may help patients and providers assess changes in severity of Parkinson disease symptoms more objectively.

The UC Health professor of neurology argued that with the current view on Parkinson disease, the field is missing the mark for disease-modifying interventions.

Study findings revealed statistically significant results at week 4 for the 100-U dose compared to placebo. The 75-U dose, while effective, did not achieve statistical significance.

The presence of REM Behavior Disorder predicted an increased risk of Parkinson disease, Lewy Body dementia, or multisystem atrophy in the largest study ever performed in people with the strange disorder. Details here. 

The finger displacement sign is a simple bedside test that can help distinguish Parkinson dementia from Alzheimer dementia.

Newly approved medications for various types of pain, generalized myasthenia gravis, and Parkinson disease will be fodder for discussion at AAN 2018. Here’s a brief overview of the therapies the FDA has approved within the past 6 months.

A study examines a possible link between lifestyle and onset of PD.

The program seeks to optimize small-molecule compounds to decrease the production of mHtt through PTC’s splicing platform.

Parkinson disease articles published in 2018 reveal deeper dives into factors that include the impact of sleep and fatigue on symptoms.

Using the NCT-504 compound to inhibit cell-signaling activity in PIP4Kγ resulted in an increase in autophagy in connective tissue cells from patients with HD.

Exposure to monesin has been shown to combat stress by oxidants and free radicals via the protein kinase R-like endoplasmic reticulum kinase/activating transcription factor 4 pathway.

A newly synthesized compound may be the basis for a novel iron-chelation therapy in several iron-associated neurodegenerative disorders, including Alzheimer, Parkinson, and Huntington disease.

Most people with Parkinson Disease develop cognitive impairment at some point. But this study provides evidence for sex differences in progression to cognitive impairment and dementia.

The FDA had accepted a new drug application for the inhaled levodopa therapy for the treatment of OFF period symptoms in patients with Parkinson disease who are taking a carbidopa/levodopa regimen.

Lower serum caffeine levels may be of diagnostic significance in early Parkinson disease, consistent with epidemiologic data that support the neuro-protective properties of caffeine.

The once-daily therapy will be available in 3 doses—129 mg, 193 mg, and 258 mg—giving patients flexibility in regimen setting among the options.